clinical trials retatrutide ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial VisualAbstract: Retatrutide reduces body weight

A.KandrataviciusL.Maia-de-OliveiraJ

Strong telemedicine integration partners with multiple telehealth platforms for streamlined patient access to peptide prescriptions

Typical treatment progression includes: Initial Dose 3 mg once daily for the first 30 days Maintenance Dose Increase to Rybelsus 7 mg once daily Some patients may later transition to 14 mg daily depending on therapeutic response and physician guidance

PubMed Sigalos JT, et al

Finally, we validated that the peptide inhibitor exhibited robust selectivity for senescent cells and efficiently disrupted FOXO4-p53 foci formation despite its short length and L-type amino acid composition